Topas Therapeutics: Funding, Investors & Team (Sep 2026)
Topas Therapeutics GmbH is a private Hamburg, Germany-based biotechnology company focused on developing products to address areas of major unmet need, including autoimmune diseases, allergies and anti-drug antibodies. The Topas Particle Conjugates technology platform induces antigen-specific immune tolerance by harnessing the liver’s natural immunology capabilities. The Company has several proprietary programs; lead product candidate TPM203 has recently entered clinical testing for pemphigus vulgaris, an orphan disease. Other programs are in anti-drug antibodies, celiac disease, Type 1 diabetes, as well as a multiple sclerosis program that is available for partnering. Topas has a research and option agreement with Eli Lilly and Company focused on antigen-specific tolerance induction and a multi-year agreement with Boehringer Ingelheim to collaborate in the field of anti-drug antibodies. Topas’ investors include: Epidarex Capital, Gimv, EMBL Ventures, Evotec and Boehringer Ingelheim Venture Fund.
Topas Therapeutics has raised $43.4M across 2 funding rounds on record, the most recent a Series B of $21.4M announced in Jul 2021.
That round is above the $8.0M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
Topas Therapeutics Company Profile and Key Stats
Latest funding round on record: Jul 2021.
Topas Therapeutics Funding Rounds
Topas Therapeutics raised $22.0M in an undisclosed round announced in Oct 2020.
9 months later, a Series B of $21.4M was announced in Jul 2021.
Topas Therapeutics Founders and Leadership Team
No contact details are on record for this team yet.
Topas Therapeutics Funding Compared to Other Biotechnology Startups
Topas Therapeutics' latest round of $21.4M is above the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like Topas Therapeutics in Biotechnology and Hamburg
Companies Similar to Topas Therapeutics
Computomics applies AI to bioinformatics data to enable rapid understanding of genomics and drive advanced…
smartbax develop novel multi-targeted, antibacterial compounds with extraordinary potency against multi-drug…
Pacifico Biolabs offers fermentation biotechnology for development, production and distribution of…
NanoStruct is a biotechnology company that develops nanostructured sensor chips to identify bacteria and…
Tacalyx, a company originating from Max-Planck-Institute of Colloids and Interfaces in Potsdam, Germany, is…
Primogene is a biotechnology company that provides ingredient development, bioprocess manufacturing, and…
Mbiomics is a company in the field of biotechnology.
At EVANIUM, we make plant compounds like polyphenols and flavonoids more effective by improving their…
Picea Biosolutions is a biotechnology firm. Based on their core platform technology, they develop tailored…
KUPANDO is a pioneering biopharmaceutical firm that is developing TLR 4/7 agonists to boost innate immunity.…
Topas Therapeutics Funding FAQs
What does Topas Therapeutics do?
Topas Therapeutics GmbH is a private Hamburg, Germany-based biotechnology company focused on developing products to address areas of major unmet need, including autoimmune diseases, allergies and anti-drug antibodies. The Topas Particle Conjugates technology platform induces antigen-specific immune tolerance by harnessing the liver’s natural immunology capabilities. The Company has several proprietary programs; lead product candidate TPM203 has recently entered clinical testing for pemphigus vulgaris, an orphan disease. Other programs are in anti-drug antibodies, celiac disease, Type 1 diabetes, as well as a multiple sclerosis program that is available for partnering. Topas has a research and option agreement with Eli Lilly and Company focused on antigen-specific tolerance induction and a multi-year agreement with Boehringer Ingelheim to collaborate in the field of anti-drug antibodies. Topas’ investors include: Epidarex Capital, Gimv, EMBL Ventures, Evotec and Boehringer Ingelheim Venture Fund.
How much funding has Topas Therapeutics raised?
Topas Therapeutics has raised $43.4M across 2 rounds on record. The most recent is a Series B of $21.4M announced in Jul 2021.
When did Topas Therapeutics last raise funding?
Topas Therapeutics' most recent funding round on record is a Series B of $21.4M, announced in Jul 2021.
Who is the CEO of Topas Therapeutics?
Klaus Martin is listed as CEO at Topas Therapeutics.
Where is Topas Therapeutics headquartered?
Topas Therapeutics is based in Hamburg, Germany.
How many employees does Topas Therapeutics have?
Topas Therapeutics is in the 51-100 employee band.
How does Topas Therapeutics' funding compare to other Biotechnology startups?
Topas Therapeutics' latest round of $21.4M is above the $8.0M median round size for Biotechnology companies on FundedIQ across 4,179 tracked companies over the last two years.
About FundedIQ's Topas Therapeutics Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Topas Therapeutics is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.
Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.